Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMedical Mutual - Ohio Gaucher oral agents Coverage…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Gaucher Disease Oral Agents (Cerdelga, miglustat, Zavesca, Yargesa)

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines recommended prior authorization and coverage criteria for the oral Gaucher disease agents Cerdelga (eliglustat) and miglustat (Zavesca, Yargesa, generics) for adults with Type I Gaucher disease; applies to pharmacy benefit coverage determinations by the payer.

    Policy Summary
    Payermedical mutual - ohio
    PolicyGaucher Disease Oral Agents (Cerdelga, miglustat, Zavesca, Yargesa)
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateDec 18, 2025
    Last ReviewDec 18, 2025
    Next Review DateDec 18, 2025
    Key ActionObtain an FDA-cleared CYP2D6 metabolizer status test result when requesting Cerdelga (eliglustat).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+minimum age for coverage
    1 yearinitial approval duration
    CYP2D6pharmacogenetic requirement
    Type II/IIInot recommended

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Oral Gaucher Therapies

    inv-01: Initial coverage criteria for Type I Gaucher disease (adults)

    Covered when ALL of the following are met

    Eligibility for Type I Gaucher disease therapy: A. Member is 18 years of age or older; AND B. Medication (Cerdelga, generic miglustat, Zavesca, or Yargesa) is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder sub-specialist, or a physician who specializes in treatment of Gaucher disease; AND C. Diagnosis of Type I Gaucher disease is established by at least one of: (a) white blood cell or skin fibroblast glucocerebrosidase activity < 30% of normal; OR (b) mutation of two glucocerebrosidase (GBA) alleles; AND D. If the request is for Cerdelga (eliglustat), the member has an FDA-cleared test showing the member's CYP2D6 metabolizer status.

    Prescribing specialist requirement and diagnostic confirmation required.

    inv-02: Continuation of therapy

    Covered when ALL of the following are met for patients already started on therapy

    Continuation/ongoing therapy: Patient was started on Cerdelga, generic miglustat, Zavesca or Yargesa for an indication addressed in this document; AND the drug continues to provide clinical benefit (e.g., improvement in symptoms, platelet count, or decrease in liver or spleen size); AND the medication continues to be prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder sub-specialist, or a physician who specializes in treatment of Gaucher disease.

    Response to therapy required for reauthorization.

    Use of Cerdelga (eliglustat), miglustat (generic, Zavesca, Yargesa) for Type II or Type III Gaucher disease is not recommended for approval. The Company determined that enzyme replacement therapy and substrate reduction therapy have not been accepted in the medical community in the United States as standard or appropriate means of treatment for these neuronopathic forms.

    Coadministration of an oral substrate reduction therapy with an enzyme replacement therapy for Gaucher disease (for example, concurrent use involving Cerdelga with Cerezyme, Elelyso, Vpriv, or other enzyme replacement products) is not recommended for coverage.

    inv-14: Adults with Type I Gaucher disease — diagnostic and CYP2D6 requirement

    Diagnostic and pharmacogenetic requirements for adults with Type I Gaucher disease: Diagnosis must be established by at least one of: (a) white blood cell or skin fibroblast glucocerebrosidase activity < 30% of normal; OR (b) mutation of two glucocerebrosidase (GBA) alleles. For requests for Cerdelga (eliglustat), an FDA-cleared test demonstrating the member's CYP2D6 metabolizer status is required.

    CYP2D6 testing must be via an FDA-cleared assay as stated in policy.

    Covered Indications

    inv-14: Adults with Type I Gaucher disease — diagnosis must be established and eliglustat requires CYP2D6 metabolizer status

    Diagnosis of Type I Gaucher disease must be established and eliglustat requires CYP2D6 testing

    Diagnostic criteria: Diagnosis of Type I Gaucher disease must be established by at least one of the following: (a) white blood cell or skin fibroblast glucocerebrosidase activity < 30% of normal; OR (b) biallelic mutation of the glucocerebrosidase (GBA) gene.

    Enzyme activity threshold per policy.

    Eliglustat pharmacogenetic requirement: Requests for eliglustat (Cerdelga) must include the member's CYP2D6 metabolizer status as determined by an FDA-cleared test (extensive, intermediate, or poor metabolizer categories per the drug indication).

    FDA-cleared CYP2D6 test result required for eliglustat approval.

    Eligibility Requirements

    Eligibility for coverage requires meeting all policy criteria for adults with Type I Gaucher disease. Specifically, the member must be 18 years of age or older; the drug (Cerdelga or miglustat products) must be prescribed by or in consultation with an appropriate specialist (a geneticist, endocrinologist, metabolic disorder sub‑specialist, or a physician who specializes in treatment of Gaucher disease); and the diagnosis of Type I Gaucher disease must be confirmed by either glucocerebrosidase enzyme activity < 30% of normal (white blood cell or skin fibroblast assay) or by biallelic mutations in the glucocerebrosidase (GBA) gene. For requests for Cerdelga (eliglustat), an FDA‑cleared CYP2D6 metabolizer status test result is required.

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization recommended

    Prior authorization is recommended for pharmacy benefit coverage of Cerdelga (eliglustat) and miglustat products; approval is recommended only for requests that meet the policy's coverage criteria and when prescribed by or in consultation with an appropriate specialist.

    Prior Authorization

    CYP2D6 testing required for Cerdelga

    An FDA-cleared CYP2D6 metabolizer status test result is required when requesting Cerdelga (eliglustat).

    • If request is for Cerdelga, member must have had an FDA-cleared test showing the member's CYP2D6 metabolizer status.
    Step Therapy

    Miglustat indication for Type I Gaucher disease (adults)

    Definitions and Disease Types

    Type I Gaucher disease (non‑neuronopathic)
    DefinitionType I (non‑neuronopathic) Gaucher disease involves visceral organs (e.g., liver, spleen), bone marrow and bone, with no central nervous system involvement.
    InheritanceAutosomal recessive lysosomal storage disorder caused by deficient glucocerebrosidase leading to glucocerebroside accumulation.
    Typical age & prevalenceCan occur at any age; most common form and seen more frequently in individuals of Ashkenazi Jewish descent.
    Clinical featuresVisceral organomegaly (liver, spleen), bone marrow involvement, bone disease; absence of neurologic involvement differentiates from neuronopathic forms.
    Type II and III Gaucher disease (neuronopathic)
    Definition (Type II)Type II is a neuronopathic (acute infantile) form with neurologic involvement that typically begins during the first year of life and is rapidly progressive (acute neuronopathic disease).

    Not Covered

    Testing or therapy with Cerdelga, miglustat, Zavesca, or Yargesa for Type II or Type III Gaucher disease is not recommended for approval and therefore is considered not covered under this policy.

    Background

    Gaucher disease is an autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme glucocerebrosidase, leading to accumulation of glucocerebroside in liver, spleen, bone marrow and bone. Type I is the non‑neuronopathic, most common form and primarily affects visceral organs and bone; Types II and III are neuronopathic forms with neurological involvement (Type II is acute infantile onset; Type III is chronic childhood‑onset). Oral substrate reduction therapies such as eliglustat (Cerdelga) and miglustat (Zavesca, Yargesa) have specific indications and limitations: approval in this policy is limited to adults with confirmed Type I Gaucher disease, while these agents and enzyme replacement therapies are not recommended for Type II or Type III disease.

    Policy Summary
    Payermedical mutual - ohio
    PolicyGaucher Disease Oral Agents (Cerdelga, miglustat, Zavesca, Yargesa)
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateDec 18, 2025
    Last ReviewDec 18, 2025
    Next Review DateDec 18, 2025
    Key ActionObtain an FDA-cleared CYP2D6 metabolizer status test result when requesting Cerdelga (eliglustat).
    SourceLink
    On This Page
    Coverage Criteria for Oral Gaucher TherapiesCovered IndicationsEligibility RequirementsProvider Actions and Documentation RequirementsDefinitions and Disease TypesNot CoveredBackground

    Miglustat is indicated for adult patients with mild to moderate Type I Gaucher disease when enzyme replacement therapy is not a therapeutic option (for example, allergy, hypersensitivity, or poor venous access).

    • Use miglustat only for adults with mild to moderate Type I Gaucher disease when ERT is unsuitable.
    Note

    Prescriber specialty requirement for initial therapy

    Initial prescriptions or consults must be from a geneticist, endocrinologist, metabolic disorder sub-specialist, or a physician who specializes in the treatment of Gaucher disease.

    • All approvals for initial therapy require the drug be prescribed by or in consultation with an appropriate specialist.
    Documentation Required

    Be prepared to provide patient records and provider credentials on request

    The Company may request additional documentation to support coverage determinations, including patient records, test results, and credentials of the provider ordering or performing the service.

    • Documentation requested may include patient records, test results and/or credentials of the provider.
    • Additional documentation supporting medical necessity must be made available upon request.
    Denial Risk

    Denial risk for lack of medical necessity or investigational use

    The Company may deny reimbursement if it determines the drug or services were not medically necessary, investigational or experimental, not within scope of benefits, or if a pattern of inappropriate or excessive billing is found.

    • Ensure documentation supports medical necessity to avoid denial.
    • Requests outside the Recommended Authorization Criteria may be subject to case-by-case review and denial.
    Denial Risk

    Not recommended for Type II or Type III Gaucher disease

    Requests for Cerdelga or miglustat for Type II or Type III Gaucher disease are listed as conditions not recommended for approval and are not supported by the policy.

    • Cerdelga, miglustat, Zavesca and Yargesa are not recommended for Type II or Type III Gaucher disease.
    • Coadministration with another enzyme replacement therapy for Gaucher disease is not recommended for coverage.
    Definition (Type III)Type III is a neuronopathic (chronic childhood‑onset) form with neurologic involvement that is typically slowly progressive and appears in early childhood (chronic neuronopathic disease).
    Shared featuresBoth Type II and III have neurologic involvement in addition to visceral, marrow, and bone manifestations seen in Type I.